The DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
Control of oncogenesis and cancer therapy resistance by the transcription factor NF-κB
Open accessAbstract
The abilities of NF-κB to promote cell proliferation, suppress apoptosis, promote cell migration, and suppress differentiation apparently have been co-opted by cellular and viral oncoproteins to promote oncogenesis (Figure 2). Direct evidence, using both in vitro and in vivo models, indicates that NF-κB is required for oncogenesis, probably at multiple levels. NF-κB likely plays an important role in the early events of oncogenesis, possibly functioning primarily in protecting against transformation-associated apoptosis. In most late-stage tumor cells, classic NF-κB (the p50-p65 heterodimer) is clearly not the only survival factor, because its inhibition does not induce apoptosis in many of these tumor cells. This observation suggests that other events have occurred to upregulate NF-κB-independent cell survival pathways. However, clearly some cancer cells depend on NF-κB for their survival. NF-κB also can contribute to cell progression by transcriptionally upregulating cyclin D1 with corresponding hyperphosphorylation of the tumor suppressor protein Rb. The induction of NF-κB-controlled proliferation may correlate with loss of differentiation in certain settings (47), which may promote oncogenesis. NF-κB is known to regulate certain genes associated with metastasis, such as matrix metalloproteinase 9, tissue plasminogen activator, and ICAM-1. Thus, a more relevant role for NF-κB in later-stage oncogenesis may be to promote metastasis and angiogenesis. Although many tumor cells display some level of constitutive nuclear NF-κB, higher levels of NF-κB and the transcriptional potential of NF-κB can be further enhanced in response to certain types of chemotherapy. Consistent with this, inhibition of NF-κB in parallel with certain (but apparently not all) chemotherapy treatments strongly enhances the apoptotic potential of the chemotherapy. This observation indicates that NF-κB plays an important role in inducible chemoresistance and establishes NF-κB inhibition as a new adjuvant approach in chemotherapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
NF-κB AND REL PROTEINS: Evolutionarily Conserved Mediators of Immune Responses
Ghosh, S., May, M. J., & Kopp, E. B. (1998) · Annual Review of Immunology · doi:10.1146/annurev.immunol.16.1.225 · Cited by 5,182
TNF- and Cancer Therapy-Induced Apoptosis: Potentiation by Inhibition of NF-κB
Wang, C.-Y., Mayo, M. W., & Baldwin, A. S. (1996) · Science · doi:10.1126/science.274.5288.784 · Cited by 2,617
Self-citationTherapeutic potential of inhibition of the NF-κB pathway in the treatment of inflammation and cancer
Yamamoto, Y., & Gaynor, R. B. (2001) · Journal of Clinical Investigation · doi:10.1172/jci11914 · Cited by 1,585
NF-κB is a target of AKT in anti-apoptotic PDGF signalling
Romashkova, J. A., & Makarov, S. S. (1999) · Nature · doi:10.1038/43474 · Cited by 1,517
Zhong, H., Voll, R. E., & Ghosh, S. (1998) · Molecular Cell · doi:10.1016/s1097-2765(00)80066-0 · Cited by 1,210
Control of apoptosis by Rel/NF-κB transcription factors
Barkett, M., & Gilmore, T. D. (1999) · Oncogene · doi:10.1038/sj.onc.1203238 · Cited by 1,204
Aberrant rel/nfkb genes and activity in human cancer
Rayet, B., & Gélinas, C. (1999) · Oncogene · doi:10.1038/sj.onc.1203221 · Cited by 1,110
Wang, C.-Y., Cusack, J. C., Liu, R., & Baldwin, A. S. (1999) · Nature Medicine · doi:10.1038/7410 · Cited by 988
Self-citationNF-κB-Induced Loss of MyoD Messenger RNA: Possible Role in Muscle Decay and Cachexia
Guttridge, D. C., Mayo, M. W., Madrid, L. V., Wang, C.-Y., & Baldwin Jr., A. S. (2000) · Science · doi:10.1126/science.289.5488.2363 · Cited by 924
Bargou, R. C., Emmerich, F., Krappmann, D., Bommert, K., Mapara, M. Y., Arnold, W., Royer, H. D., Grinstein, E., Greiner, A., Scheidereit, C., et al. (1997) · Journal of Clinical Investigation · doi:10.1172/jci119849 · Cited by 761
Role of NF-κB in p53-mediated programmed cell death
Ryan, K. M., Ernst, M. K., Rice, N. R., & Vousden, K. H. (2000) · Nature · doi:10.1038/35009130 · Cited by 740
Cdc42 and Rac1 induce integrin-mediated cell motility and invasiveness through PI(3)K
Keely, P. J., Westwick, J. K., Whitehead, I. P., Der, C. J., & Parise, L. V. (1997) · Nature · doi:10.1038/37656 · Cited by 732
Kasibhatla, S., Brunner, T., Genestier, L., Echeverri, F., Mahboubi, A., & Green, D. R. (1998) · Molecular Cell · doi:10.1016/s1097-2765(00)80054-4 · Cited by 721
Aberrant nuclear factor-kappaB/Rel expression and the pathogenesis of breast cancer.
Sovak, M. A., Bellas, R. E., Kim, D. W., Zanieski, G. J., Rogers, A. E., Traish, A. M., & Sonenshein, G. E. (1997) · Journal of Clinical Investigation · doi:10.1172/jci119848 · Cited by 720
Hostile takeovers: viral appropriation of the NF-kB pathway
Hiscott, J., Kwon, H., & Génin, P. (2001) · Journal of Clinical Investigation · doi:10.1172/jci11918 · Cited by 613
Transcriptional Cross Talk between NF-κB and p53
Webster, G. A., & Perkins, N. D. (1999) · Molecular and Cellular Biology · doi:10.1128/mcb.19.5.3485 · Cited by 598
Madrid, L. V., Wang, C.-Y., Guttridge, D. C., Schottelius, A. J. G., Baldwin, A. S., & Mayo, M. W. (2000) · Molecular and Cellular Biology · doi:10.1128/mcb.20.5.1626-1638.2000 · Cited by 540
Self-citationRequirement of NF-κB Activation to Suppress p53-Independent Apoptosis Induced by Oncogenic Ras
Mayo, M. W., Wang, C.-Y., Cogswell, P. C., Rogers-Graham, K. S., Lowe, S. W., Der, C. J., & Baldwin, A. S. (1997) · Science · doi:10.1126/science.278.5344.1812 · Cited by 533
Self-citationHolmes-McNary, M. Q., & Baldwin, A. S. (2000) · PubMed · doi:10.17615/wdcc-wb89 · Cited by 498
Self-citationCogswell, P. C., Guttridge, D. C., Funkhouser, W. K., & Baldwin, A. S. (2000) · Oncogene · doi:10.1038/sj.onc.1203412 · Cited by 452
Self-citationSeitz, C. S., Lin, Q., Deng, H., & Khavari, P. A. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.5.2307 · Cited by 436
A requirement for NF-kappa B activation in Bcr-Abl-mediated transformation
Reuther, J. Y., Reuther, G. W., Cortez, D., Pendergast, A. M., & Baldwin Jr., A. S. (1998) · Genes & Development · doi:10.1101/gad.12.7.968 · Cited by 392
Finco, T. S., Westwick, J. K., Norris, J. L., Beg, A. A., Der, C. J., & Baldwin, A. S. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.39.24113 · Cited by 375
Self-citationHER-2/neu Blocks Tumor Necrosis Factor-induced Apoptosis via the Akt/NF-κB Pathway
Zhou, B. P., Hu, M. C.-T., Miller, S. A., Yu, Z., Xia, W., Lin, S.-Y., & Hung, M.-C. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.275.11.8027 · Cited by 371
Mutations in the IkBa gene in Hodgkin's disease suggest a tumour suppressor role for IκBα
Cabannes, E., Khan, G., Aillet, F., Jarrett, R. F., & Hay, R. T. (1999) · Oncogene · doi:10.1038/sj.onc.1202893 · Cited by 334
Bridging the Gap: Composition, Regulation, and Physiological Function of the IκB Kinase Complex
Zandi, E., & Karin, M. (1999) · Molecular and Cellular Biology · doi:10.1128/mcb.19.7.4547 · Cited by 321
Patel, N. M., Nozaki, S., Shortle, N. H., Bhat-Nakshatri, P., Newton, T. R., Rice, S., Gelfanov, V., Boswell, S. H., Goulet, R. J., Sledge, G. W., et al. (2000) · Oncogene · doi:10.1038/sj.onc.1203768 · Cited by 294
van Hogerlinden, M., Rozell, B., Ährlund‐Richter, L., & Toftgård, R. (1999) · PubMed · Cited by 277
Rel/NF-kappaB/IkappaB proteins and cancer.
Gilmore, T. D., Koedood, M., Piffat, K. A., & White, D. W. (1996) · PubMed · Cited by 274
Duffey, D. C., Chen, Z., Dong, G., Ondrey, F. G., Wolf, J. S., Brown, K., Siebenlist, U. K., & Waes, C. V. (1999) · PubMed · Cited by 263
NF-κB inhibition causes spontaneous apoptosis in Epstein–Barr virus-transformed lymphoblastoid cells
Cahir-McFarland, E. D., Davidson, D. M., Schauer, S. L., Duong, J., & Kieff, E. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.100119497 · Cited by 259
Huang, S., DeGuzman, A., Bucana, C. D., & Fidler, I. J. (2000) · PubMed · Cited by 250
Kasibhatla, S., Genestier, L., & Green, D. R. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.2.987 · Cited by 250
Yamaoka, S., Inoue, H., Sakurai, M., Sugiyama, T., Hazama, M., Yamada, T., & Hatanaka, M. (1996) · The EMBO Journal · doi:10.1002/j.1460-2075.1996.tb00422.x · Cited by 183
Ishikawa, H., Carrasco, D., Claudio, E., Ryseck, R.-P., & Bravo, R. (1997) · The Journal of Experimental Medicine · doi:10.1084/jem.186.7.999 · Cited by 176
Huang, Y., Johnson, K. R., Norris, J. S., & Fan, W. (2000) · PubMed · Cited by 163
Cusack, J. C., Liu, R., & Baldwin, A. S. (2000) · PubMed · Cited by 160
Self-citationChu, Z., DiDonato, J. A., Hawiger, J., & Ballard, D. W. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.26.15891 · Cited by 150
Norris, J. L., & Baldwin, A. S. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.20.13841 · Cited by 147
Self-citationTakeshita, H., Yoshizaki, T., Miller, W. E., Sato, H., Furukawa, M., Pagano, J. S., & Raab‐Traub, N. (1999) · Journal of Virology · doi:10.1128/jvi.73.7.5548-5555.1999 · Cited by 127
Arsura, M., Mercurio, F., Oliver, A. L., Thorgeirsson, S. S., & Sonenshein, G. E. (2000) · Molecular and Cellular Biology · doi:10.1128/mcb.20.15.5381-5391.2000 · Cited by 119
Structural alterations of the NF-kappa B transcription factor lyt-10 in lymphoid malignancies.
Ns, F., Lombardi, L. T., Salina, M., Migliazza, A., Baldini, L., Berti, E., Cro, L., Polli, E. E., Maiolo, A. T., & Neri, A. (1993) · PubMed · Cited by 106
NF- κ B and chemoresistance: potentiation of cancer drugs via inhibition of NF- κ B
Cusack, J. C., Liu, R., & Baldwin, A. S. (1999) · Drug Resistance Updates · doi:10.1054/drup.1999.0094 · Cited by 86
Self-citationRivera-Walsh, I., Cvijic, M. E., Xiao, G., & Sun, S. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m000444200 · Cited by 55
Ciana, P., Neri, A., Cappellini, C., Cavallo, F., Pomati, M., Chang, C., Maiolo, A. T., & Lombardi, L. (1997) · Oncogene · doi:10.1038/sj.onc.1201015 · Cited by 40
Cited by
The Bcl2 family: regulators of the cellular life-or-death switch
Cory, S., & Adams, J. M. (2002) · Nature Reviews Cancer · doi:10.1038/nrc883 · Cited by 4,032
Rosenwald, A., Wright, G., Chan, W. C., Connors, J. M., Campo, E., Fisher, R. I., Gascoyne, R. D., Muller-Hermelink, H. K., Smeland, E. B., Giltnane, J. M., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa012914 · Cited by 3,829
Modulation of NF‐κB‐dependent transcription and cell survival by the SIRT1 deacetylase
Yeung, F., Hoberg, J. E., Ramsey, C. S., Keller, M. D., Jones, D. R., Frye, R. A., & Mayo, M. W. (2004) · The EMBO Journal · doi:10.1038/sj.emboj.7600244 · Cited by 2,750
NF-κB at the crossroads of life and death
Karin, M., & Lin, A. (2002) · Nature Immunology · doi:10.1038/ni0302-221 · Cited by 2,709
NF-κB functions as a tumour promoter in inflammation-associated cancer
Pikarsky, E., Porat, R. M., Stein, I., Abramovitch, R., Amit, S., Kasem, S., Gutkovich-Pyest, E., Urieli-Shoval, S., Galun, E., & Ben-Neriah, Y. (2004) · Nature · doi:10.1038/nature02924 · Cited by 2,430
Metadata
- Authors
- Baldwin, A. S.
- Venue
- Journal of Clinical Investigation
- Published
- 2001-02-01
- Volume
- 107
- Issue
- 3
- Pages
- 241-246
- ISSN
- 0021-9738 (ISSN-L)
- OpenAlex
- W2051994734
- Cited by
- 1,434
- References
- 45
- FWCI
- 40.06
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.